GYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
GYRE THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$6.09+0.01 (+0.16%)
Close on Oct 19, 2026
- Market cap
- $612.88M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$2.21 (−26.63%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
GYRE THERAPEUTICS, INC. grew revenue 13.5% to $119.38M over the twelve months to Jun 30, 2026. Operating income fell 438.2% to -$16.68M, moving the operating margin from 4.7% to -14.0%. Free cash flow was -$6.11M.
Revenue
$119.38M
+13.5% vs. a year earlier
Operating income
-$16.68M
-438.2% vs. a year earlier
Free cash flow
-$6.11M
TTM Q2 2026
EPS, diluted
-$0.21
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $612.88M
- P/E ratio
- –
- Price to sales
- 5.13
- Price to book
- 5.68
- Dividend yield
- –
- Free cash flow yield
- -1.00%
Fundamentals
- Revenue
- $119.38M
- Net income
- -$28.23M
- EPS, diluted
- -$0.21
- Free cash flow
- -$6.11M
- Book value per share
- $1.07
- Diluted shares
- 101M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$119.38M+13.5% YoY
Gross profit
$112.58M+14.9% YoY
Operating income
-$16.68M-438.2% YoY
Net income
-$28.23M-558.6% YoY
EPS, diluted
-$0.21
Free cash flow
-$6.11M
Reported periodTrailing twelve months